BioLineRx (BLRX) Research & Development (2011 - 2026)

BioLineRx's Research & Development history runs 14 years deep, the most recent figure standing at -$2.4 million for Q4 2025.

• In Q4 2025, Research & Development fell 30.03% year-over-year to -$2.4 million; the TTM figure through Dec 2025 stood at -$8.1 million (up 11.54% YoY), while the FY2025 annual figure was -$8.1 million, up 11.54% from the prior year.
• Research & Development for Q4 2025 stood at -$2.4 million, down from -$1.7 million in the prior quarter.
• The five-year high for Research & Development was $5.4 million in Q2 2022, with the low at -$5.1 million in Q4 2021.
• The 5-year median for Research & Development is -$2.6 million (2023), against an average of -$2.3 million.
• The sharpest annual moves came in 2023 and 2024: Research & Development slumped 155.72% in 2023, then surged 39.88% in 2024.
• BioLineRx's Research & Development stood at -$5.1 million in 2021, then surged by 33.09% to -$3.4 million in 2022, then gained by 9.56% to -$3.1 million in 2023, then soared by 39.88% to -$1.9 million in 2024, then slumped by 30.03% to -$2.4 million in 2025.
• Business Quant data shows BLRX's Research & Development at -$2.4 million in Q4 2025, -$1.7 million in Q3 2025, and -$2.3 million in Q2 2025.